A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

NCT06566742 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
Clonal Cytopenia of Undetermined Significance

Interventions

DRUG: Olutasidenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]